Repurposing daclatasvir for MASLD Therapy—A promising step forward with challenges ahead [PDF]
Journal of Lipid ResearchThe article discusses the potential of repurposing daclatasvir, an FDA-approved anti-HCV drug, for treating metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH ...
Carlos Jose Pirola
doaj +3 more sources
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
New Microbes and New Infections, 2021 Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae ...
M Shabani
exaly +4 more sources
Hepatoprotective drug screening identifies daclatasvir, a promising therapeutic candidate for MASLD by targeting PLIN2 [PDF]
Journal of Lipid ResearchMetabolic dysfunction-associated steatohepatitis (MASH) has become a global health challenge with limited therapeutic strategy. Here, this study aims to identify promising drug candidates for MASH and clarify its pharmacological mechanism.
Rui Shu +15 more
doaj +2 more sources
The Effectiveness of a Sofosbuvir/Daclatasvir Combination in the Treatment of HCV Infection in Patients from Mauritania Undergoing Chronic Hemodialysis [PDF]
MedicinaBackground and Objectives: Hepatitis C virus (HCV) infection is highly prevalent among patients undergoing chronic hemodialysis in emerging countries and is associated with significant morbidity and mortality in this population.
Sidi Mohamed Mah +6 more
doaj +2 more sources
Efficacy and safety of sofosbuvir plus daclatasvir in hemodialysis patients with genotype 1b or 2a hepatitis C virus infection: a single-arm, prospective real-world study [PDF]
Frontiers in MedicineBackground/aimsThis investigation assessed the clinical outcomes and adverse effects of combination therapy using sofosbuvir (SOF) and daclatasvir (DCV) among dialysis-dependent patients infected with hepatitis C virus (HCV) genotypes 1b or 2a in real ...
Kaili Wang +4 more
doaj +2 more sources
EVALUATION OF THE SAFETY AND RESISTANCE ASSOCIATED VARIANTS OF SOFOSBUVIR/DACLATASVIR AMONG EGYPTIAN PATIENTS WITH HEPATITIS C VIRUS: A PROSPECTIVE STUDY [PDF]
Bulletin of Pharmaceutical Sciences. Assiut University, 2022 Background: Hepatitis C virus (HCV) is a major health problem. Current treatment by direct-acting antivirals achieved high sustained virological response (SVR). However, drug intolerance or relapse may occur.
, Soha Abdel-Monem +5 more
doaj +1 more source
Archives of Pharmaceutical Sciences Ain Shams University, 2022 Renal Organic Cation Transporter 2 (OCT2) plays a major role in metformin elimination. Daclatasvir, a Direct-Acting Antiviral (DAA), is an OCT2 inhibitor.
Mohamed Raslan +2 more
doaj +1 more source
BMC Chemistry, 2023 Background Daclatasvir dihydrochloride has important roles not only in the management of COVID-19 pandemic symptoms but also in the treatment of chronic hepatitis C infection.
Rania A. Sayed +3 more
doaj +1 more source
Journal of Infection in Developing Countries, 2021 Introduction: The conventional interferon therapy of hepatitis C virus has been substituted substantially with sofosbuvir and daclatasvir due to constraints in efficacy and tolerability.
Sonia Younas +7 more
doaj +1 more source